AHA Enduring Webinar: Spotlight Series - Stroke Prevention in Atrial Fibrillation: New Concepts, Treatments, and Challenges
Anticoagulation is an important consideration in the management of atrial fibrillation. The goal of this accredited education program will be stroke prevention in atrial fibrillation including factors contributing to stroke risk, bleeding risk in AF patients and issues related to appropriate anticoagulants.
About the Activity

Spotlight Series - Stroke Prevention in Atrial Fibrillation: New Concepts, Treatments, and Challenges 

Participation and Successful Completion
Successful completion of this CE activity includes the following: (1) Register and view the course online. (2) Complete the evaluation survey (3) Print your CME/CE Certificate from your own printer.  There is no fee for CME/CE credits for this activity.  The link to the CME/CE “Lifelong Learning” website is learn.heart.org.

Hardware/Software Requirements
Internet Explorer 7 or greater, Firefox (Latest Version), Google Chrome, Windows 7 or above, Safari (Latest Version), Adobe Acrobat Reader, Internet Explorer is not supported on the Macintosh, Mac OS 10.4

Cost to Attend
There is no fee for CME/CE credits for this activity.

Target Audience
Physicians - Cardiology, Primary Care/Family Practice
Nurse Practitioners - Cardiology, Primary Care/Family Practice                           
Nurses -  Cardiology, Primary Care/Family Practice
Pharmacists - Cardiology, Primary Care/Family Practice

Description
Spotlight Series, which began in 2008, offers free, case-based presentations designed to educate healthcare providers on evidence-based practices. The target audience includes internists, family practice physicians and other primary care physicians; cardiologists, nurses, pharmacists, physician’s assistants and other clinicians involved in the treatment of patients with or at risk for cardiovascular disease

Anticoagulation is an important consideration in the management of atrial fibrillation. The goal of this accredited education program will be stroke prevention in atrial fibrillation including factors contributing to stroke risk, bleeding risk in AF patients and issues related to appropriate anticoagulants.

Learning Objectives 
At the completion of this course, the learner will be able to:

  1. Identify factors contributing to stroke risk in patients with atrial fibrillation (AF).
  2. Discuss factors that increase risk of bleeding in patients with AF.
  3. Assess issues related to appropriate individualized selection of warfarin or target-specific oral anticoagulants.


Course Agenda

Time

Presentation Title

Faculty

Corresponding learning Objective (list by number)

60 minutes

Stroke Prevention in Atrial Fibrillation: New Concepts, Treatments, and Challenges

Mintu Turakhia

1-3


Faculty
Mintu Turakhia, MD, MAS, FAHA
Palo Alto VA Health Care System
Stanford University

Disclosures

Faculty Member

Employment

Research Grant

Consultant/
Advisory Board

Stock Shareholder (directly purchased)

Honoraria

Other Speaker’s Bureau

Mintu Turakhia

Palo Alto VA Health Care System

Medtronic, iRhythm, Gilead Sciences, SentreHeart

St. Jude Medical, Precision Health Economics, Medtronic, Janssen

None

St. Jude Medical, Precision Health Economics, Medtronic, Janssen

None

Carmen Kaufman

Rush-Copely Medical Center

None

None

None

None

None

Richard Becker

Univ of Cincinnati College of Medicine

None

Bayer, Daiichi-Sankyo

None

None

Portola

Jared Bunch

Intermountain Heart Institute Rhythm Specialists

None

None

None

None

None

Rakesh Gopinathannair

University of Louisville School of Medicine & Jewish Hospita

None

St. Jude Medical, Abiomed, Inc.

None

None

Pfizer/Bristol Myers Squibb

Saman Nazarian

John Hopkins University School of Medicine

Biosense Webster

Biosense Webster, Medtronic, CardioSolv

None

None

None

Jonathan Hsu

University of California, San Diego

None

Celladon, Janssen Pharmaceuticals

None

Medtronic, St. Jude Medical

None

Michael D. Ezekowitz

Sidney Kimmel Medical College at Jefferson University

Lankenau Medical Center, Bryn Mawr and Paoli Hospitals

None

BI, Pfizer Sanofi, Bristol Myers Squibb, Portola, Bayer, Daiichi Sankyo, Medtronic, Aegerion, Merck, J&J, Gilead, Janssen Scientific Affairs, Pozen, Inc, Amgen, Coherex, Armetheon

None

None

None

Bassam A. Omar

University of South Alabama Health System

None

None

None

None

None

Greg Flaker

University of Missouri

Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer

Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Daiichi Sankyo

None

None

None

Jonathan P. Piccini Sr

Duke Univeristy Medical Center

Janssen Pharma, ARCA Biopharma, Boston Scientific, ResMed, GE Healthcare, Medtronic, Spectranetics, Johnson & Johnson

None

None

None

None

Peter Kowey

Lankenau Institute for Medical Research

None

BMS, Pfizer, B-I, J & J, Daichi-Sankyo, Merck, Boston Sci

None

BMS, Pfizer, B-I, J & J, Daiichi-Sankyo, Merck, Boston Sci

BMS, B-I

Jonathan Halperin

Mount Sinai Medical Center

None

Bayer AG Healthcare,Boehringer Ingelhei, Daiichi Sankyo, Johnson & Johnson, Ortho-McNeil-Janssen Pharma, Pfizer, Sanofi-Aventis, AstraZeneca, Biotronik, Boston Scientific, Janssen, Medtronic

None

None

None

Chris Flores

Loma Linda University School of Medicine

None

None

None

None

None

Arthur L Allen

VA Sierra Nevada Health Care System

None

None

None

None

Janssen

Jennifer Sydenham

VA Palo Alto Health Care System

None

None

None

None

None

This table represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.


Accreditation Statements:
ORIGINAL RELEASE DATE:  2/1/2017
TERMINATION DATE:  2/2/2020
LAST REVIEW DATE: January 2017
JOINT ACCREDITATION TERM: 02/02/2017 –02/02/2020

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours.  Universal Program Number: 0256-000-17-H01-P **ACPE Credit must be claimed within 30 days of participation. ACPE credit will no longer be available to claim after the 30 day claiming period.

Continuing Medical Education Accreditation - Physicians
This Enduring Material activity, Spotlight Series: Stroke Prevention in Atrial Fibrillation: New Concepts, Treatments, and Challenges , has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 02/02/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Medium
This activity is a live or a virtual link activity depending on the location.
 

Contact Information
To contact the American Heart Association for any questions, please call our customer support center at 888-242-2453.
 

Policy on Privacy and Confidentiality:
Please see the privacy link at the bottom of the Professional Education Center.
 

Copyright Information
Please see the link at the bottom of the Professional Education Center.

Commercial Support
This activity is supported by independent medical educational grants from Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership and Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Information
ACCME > AMA PRA Category 1 Credit
Available: 1 Credits
Earned: 0 Credits
Release Date: 2/1/2017
Expiration Date: 2/2/2020

ACPE > ACPE
Available: 1 Contact Hours
Earned: 0 Contact Hours
Release Date: 2/1/2017
Expiration Date: 2/2/2020

AHA > AHA
Available: 0 Credits
Earned: 0 Credits
Release Date: 2/1/2017
Expiration Date: 2/2/2020

ANCC > ANCC
Available: 1 Contact Hours
Earned: 0 Contact Hours
Release Date: 2/1/2017
Expiration Date: 2/2/2020

ACCME > Attendance Credit
Available: 1 Credits
Earned: 0 Credits
Release Date: 2/1/2017
Expiration Date: 2/2/2020

AAFP > Prescribed
Available: 1 Credits
Earned: 0 Credits
Release Date: 2/2/2017
Expiration Date: 2/2/2018